The 5-year analysis of Nectar Lifesciences Ltd's performance infers:
We analysed the performance of Nectar Lifesciences Ltd share prices over the last 10 years. Here is what we found out:
Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv Goyal.
NecLife is among few Indian manufacturers to develop, manufacture and market Oral and Sterile Cephalosporins and Semi Synthetic Penicillins. The company is amongst the few life saving API
NecLife is among few Indian manufacturers to develop, manufacture and market Oral and Sterile Cephalosporins and Semi Synthetic Penicillins. The company is amongst the few life saving API manufacturing companies that produces sterile APIs, through both Lyophilization and Crystallization processes.
Headquartered in Chandigarh, the company's manufacturing facilities are located at Derabassi (API and Menthol), Baddi (FDF and EHGC) and Jammu (Menthol). The company's marketing offices are situated at Delhi, Mumbai and Indore.
NecLife has received two star â€˜Export Houseâ€™ status from the Government of India. The company has received ISO 9001:2000 certification for quality management. The companyâ€™s manufacturing facilities for APIs were developed as per USFDA /EDQM guidelines. These facilities have also been certified by WHO GMP. The company also has a well equipped R&D unit that focuses on development of new molecules.
NecLifeâ€™s products have export presence in over 45 countries spread across 5 continents.
Besides India, Nectar Lifesciences plans to explore the untapped markets in regions namely Russia and CIS, China, Asia and USA.